Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis
- PMID: 30759966
- PMCID: PMC6823564
- DOI: 10.3904/kjim.2018.120
Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis
Abstract
Background/aims: Non-selective β-blockers (NSBBs) are used for primary prevention of esophageal variceal hemorrhage (VH) in patients with portal hypertension, but a significant number of patients develop VH while on NSBB therapy. In this study, we sought to determine whether liver volume can predict the risk of primary prophylaxis failure in cirrhotic patients on NSBB therapy.
Methods: A retrospective cohort of 309 patients on prophylactic propranolol was analyzed. Liver volume was measured in portal venous phase images of multidetector computed tomography. Predictors of VH were assessed using a Cox proportional hazards model with competing-risks analysis. A nomogram was developed for estimation of the risk of primary prophylaxis failure.
Results: During a median follow-up of 36 months, 37 patients on propranolol developed VH. Liver volume index, the ratio of measured-to-expected liver volume, was an independent predictor of VH (adjusted hazard ratio [HR], 2.70; 95% confidence interval [CI], 1.37 to 5.33; p = 0.004) as were the presence of large varices and the absence of ascites. A nomogram-based volume score of > 0.6 was predictive of prophylaxis failure (HR, 7.54; 95% CI, 2.88 to 19.73; p < 0.001). Time-dependent receiver operating characteristic curve analysis revealed that a nomogram-based risk score had significantly better discriminatory power than the North Italian Endoscopy Club index in predicting prophylaxis failure at 6 and 8 years.
Conclusion: Liver volume index is an independent predictor of first VH and a nomogram-based volume score stratifies the VH risk in cirrhotic patients on propranolol prophylaxis.
Keywords: Adrenergic beta-antagonists; Cone-beam computed tomography; Decision support techniques; Esophageal and gastric varices.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures





Similar articles
-
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.J Hepatol. 2019 Mar;70(3):412-422. doi: 10.1016/j.jhep.2018.10.018. Epub 2018 Oct 31. J Hepatol. 2019. PMID: 30389550
-
Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.Gastroenterology. 2009 Jul;137(1):119-28. doi: 10.1053/j.gastro.2009.03.048. Epub 2009 Apr 1. Gastroenterology. 2009. PMID: 19344721 Clinical Trial.
-
Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers.Am J Gastroenterol. 2016 Dec;111(12):1778-1787. doi: 10.1038/ajg.2016.440. Epub 2016 Sep 27. Am J Gastroenterol. 2016. PMID: 27670600
-
Carvedilol and traditional nonselective beta blockers for the secondary prophylaxis of variceal hemorrhage and portal hypertension related complications among patients with decompensated cirrhosis: a systematic review and network meta-analysis.Hepatol Int. 2025 Jun;19(3):647-661. doi: 10.1007/s12072-025-10812-8. Epub 2025 Apr 3. Hepatol Int. 2025. PMID: 40178720
-
Beta-blockers for prophylaxis of bleeding from esophageal varices in cirrhotic portal hypertension. Review of the literature.Eur J Med Res. 1996 Jun 25;1(9):407-16. Eur J Med Res. 1996. PMID: 9353240 Review.
Cited by
-
A novel prognostic model for predicting the risk of first variceal hemorrhage in patients with HBV-related cirrhosis.Front Cell Infect Microbiol. 2023 Jan 17;13:1062172. doi: 10.3389/fcimb.2023.1062172. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 36733609 Free PMC article.
-
Platelet Count/Spleen Thickness Ratio and the Risk of Variceal Bleeding in Cirrhosis With Esophagogastric Varices.Front Med (Lausanne). 2022 Jul 14;9:870351. doi: 10.3389/fmed.2022.870351. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35911391 Free PMC article.
-
Combinations of liver lobe and spleen volumes obtained on magnetic resonance imaging to predict esophagogastric variceal bleeding in hepatitis B-related cirrhotic patients: A prospective cohort study.Medicine (Baltimore). 2022 Sep 23;101(38):e30616. doi: 10.1097/MD.0000000000030616. Medicine (Baltimore). 2022. PMID: 36197258 Free PMC article.
-
An improved model based on quantitative features of right liver lobe, maximum varices, and portal vein system measured on magnetic resonance imaging to predict oesophagogastric variceal haemorrhage secondary to hepatitis B-related cirrhosis.Quant Imaging Med Surg. 2023 Dec 1;13(12):7741-7752. doi: 10.21037/qims-23-353. Epub 2023 Oct 20. Quant Imaging Med Surg. 2023. PMID: 38106265 Free PMC article.
-
The impact of hepatic and splenic volumetric assessment in imaging for chronic liver disease: a narrative review.Insights Imaging. 2024 Jun 18;15(1):146. doi: 10.1186/s13244-024-01727-3. Insights Imaging. 2024. PMID: 38886297 Free PMC article. Review.
References
-
- Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–335. - PubMed
-
- de Franchis R, Baveno VI Faculty Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop. Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–752. - PubMed
-
- Simonetto DA, Shah VH, Kamath PS. Primary prophylaxis of variceal bleeding. Clin Liver Dis. 2014;18:335–345. - PubMed
-
- Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990;99:1401–1407. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical